Medical and Pharmaceutical Industry Technology and Development Center Patent applications |
Patent application number | Title | Published |
20150306167 | ALPINIA SPP. EXTRACTS FOR TREATING IRRITABLE BOWEL SYNDROME - Disclosed herein is the use of an extract from | 10-29-2015 |
20140314867 | VITAMIN K2 MICROSPHERES - A vitamin K | 10-23-2014 |
20110038966 | USE OF A POTENT PRODUCT EXTRACTED FROM RHIZOMES OF ZINGIBER OFFICINALE IN TREATING A DISEASE ASSOCIATED WITH HELICOBACTER PYLORI - A new use of a potent product extracted from rhizomes of | 02-17-2011 |
20100292257 | USES OF 2-[PIPERIDINYL] METHYL-2, 3-DIHYDROIMIDAZO [1,2-C] QUINAZOLIN-5 (6H)-ONE FOR PROVIDING AN ANALGESIC EFFECT, ANTI-ALLERGIC EFFECT AND HISTAMINE H1 RECEPTOR ANTAGONISM EFFECT - The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H | 11-18-2010 |
20100166898 | ANTI-BACTERIAL USE OF EXTRACT FROM MORUS AUSTRALIS POIR. AND COMPOUND KUWANON H - An extract prepared from the root barks of | 07-01-2010 |
20090104293 | Use of a potent product extracted from rhizomes of Zingiber officinale in treating a disease associated with Helicobacter pylori - The present invention discloses a new use of a potent product extracted from rhizomes of | 04-23-2009 |
20090082373 | Uses of 2-[piperidinyl]methyl-2, 3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an analgesic effect, anti-allergic effect and histamine H1 receptor antagonism effect - The present invention discloses new uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one in providing an analgesic effect in a patient, treating passive cutaneous anaphylaxis in a patient, and in eliciting a histamine H | 03-26-2009 |
20090053287 | POROUS DRESSING - A porous dressing is provided. The porous dressing includes a polymeric layer, a pharmaceutically active ingredient and a metal oxide. The polymeric layer has a porosity and a bio-compatibility, and the pharmaceutically active ingredient and the metal oxide distribute in one selected from a group consisting of in the polymeric layer, on a surface of the polymeric layer and a combination thereof. | 02-26-2009 |